Cranswick plc (LON:CWK – Get Free Report) insider Christopher Aldersley sold 16,500 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of GBX 4,910 ($65.68), for a total value of £810,150 ($1,083,667.74).
Cranswick Stock Up 1.4 %
CWK traded up GBX 70 ($0.94) during trading on Tuesday, reaching GBX 5,090 ($68.08). 81,034 shares of the stock traded hands, compared to its average volume of 139,378. Cranswick plc has a fifty-two week low of GBX 3,392 ($45.37) and a fifty-two week high of GBX 5,110 ($68.35). The stock’s 50-day simple moving average is GBX 4,591.14 and its two-hundred day simple moving average is GBX 4,412.69. The company has a debt-to-equity ratio of 13.88, a current ratio of 1.66 and a quick ratio of 1.02. The stock has a market cap of £2.73 billion, a price-to-earnings ratio of 2,423.81, a price-to-earnings-growth ratio of 2.62 and a beta of 0.44.
Analyst Ratings Changes
Several brokerages have recently commented on CWK. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 50 ($0.67) target price on shares of Cranswick in a research report on Monday, July 29th. Shore Capital reissued a “house stock” rating on shares of Cranswick in a research report on Monday, July 29th.
About Cranswick
Cranswick plc manufactures and supplies food products to grocery retailers, food service sector, and other food producers in the United Kingdom, Continental Europe, and internationally. The company offers fresh pork, gourmet bacon and gammon, fresh and coated chicken, ready to eat chicken, charcuterie, houmous and dips, and olives and antipasti, gourmet sausages, cooked meats, and gourmet pastries, as well as provides food services.
Further Reading
- Five stocks we like better than Cranswick
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Industrial Products Stocks Investing
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Cranswick Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cranswick and related companies with MarketBeat.com's FREE daily email newsletter.